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“The most fruitful basis for the discovery of a new drug
is to start with an old one” is a citation from Sir James
Black’s Nobel laureate (1988).
The background of this statement lies in the fact that
most drugs are able to bind to multiple protein targets in
the human body, this is known as polypharmacology.
This behaviour can lead to unwanted side effects, and
innovative research to avoid such adverse properties is of
great importance. Paradoxically, polypharmacology can
also be used to create new therapeutic approaches, as the
protein to which a drug binds causing a side effect in one
case, can be the main target for another treatment. Many
cases report about the problems and opportunities of
polypharmacology.
Aims
In order for a drug to bind to multiple targets, the interac-
tion sites of these targets must be similar on a molecular
level. Using KRIPO (Key Representation of Interaction in
POckets) [1] with specially developed pharmacophore fin-
gerprints, we provide an objective method to accurately
describe protein interactions.
Results
KRIPO was used to explain the molecular mechanism of
adverse drug effects of HMG-CoA reductase inhibitors,
better known as statins. A previously unknown binding
site for statins in cytochrome b, the major subunit of
mitochondrial complex III of the oxidative phosphoryla-
tion system, was predicted by KRIPO.
Conclusion
Combining docking studies with KRIPO and experimen-
tal data on complex III inhibition enabled us to explain
the molecular details of statin binding to the predicted
binding site.
Authors’ details
1Computational Discovery and Design (CDD) Group at the Centre for
Molecular and Biomolecular Informatics (CMBI),UMC Nijmegen, The
Netherlands. 2Dept. of Pharmacology and Toxicology, UMC, Nijmegen, the
Netherlands. 3Centre for Systems Biology and Bioenergetics, UMC, Nijmegen,
the Netherlands.
Published: 11 March 2014
Reference
1. Wood DJ, de Vlieg J, Wagener M, Ritschel T: Pharmacophore Fingerprint-
Based Approach to Binding Site Subpocket Similarity and Its Application
to Bioisostere Replacement. J Chem Inf Model 2012, 52:2031-2043.
doi:10.1186/1758-2946-6-S1-O26
Cite this article as: Ritschel et al.: KRIPO – a structure-based
pharmacophores approach explains polypharmacological effects. Journal
of Cheminformatics 2014 6(Suppl 1):O26.
Open access provides opportunities to our 
colleagues in other parts of the globe, by allowing 
anyone to view the content free of charge.
Publish with ChemistryCentral and every
scientist can read your work free of charge
W. Jeffery Hurst, The Hershey Company.
available free of charge to the entire scientific community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours     you keep the copyright
Submit your manuscript here:
http://www.chemistrycentral.com/manuscript/
* Correspondence: t.ritschel@umcn.ru.nl
1Computational Discovery and Design (CDD) Group at the Centre for
Molecular and Biomolecular Informatics (CMBI),UMC Nijmegen, The
Netherlands
Full list of author information is available at the end of the article
Ritschel et al. Journal of Cheminformatics 2014, 6(Suppl 1):O26
http://www.jcheminf.com/content/6/S1/O26
© 2014 Ritschel et al; licensee Chemistry Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
